

23rd May, 2016

The Dy. General Manager (Listing Dept.)
BSE Limited.,
Corporate Relationship Dept.,
1st Floor, New Trading Ring,
P. J. Towers, Dalal Street, Fort,
Mumbai - 400 001
(BSE Scrip Code: 500420)

The Manager – Listing Dept., National Stock Exchange of India Ltd., Exchange Plaza, 5th Floor, Plot No. C/1, G. Block, Bandra - Kurla Complex, Bandra (E), Mumbai – 400 051 (NSE Scrip Code: TORNTPHARM)

Dear Sir,

Sub.: Submission / Intimation under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), 2015, ("SEBI Regulations") of Audited Financial Results (standalone and consolidated) for the quarter and year ended on 31st March, 2016

In continuation to our letter dated 06th May, 2016 intimating about the Board meeting to be held on Monday, 23rd May, 2016, we would like to inform that the Board meeting commenced at 02:30 pm and concluded at 05:30 pm, and it considered and approved the following:

1. Audited Financial Results (both standalone & consolidated) of the Company along with audit report for the quarter and year ended on 31st March, 2015 as per Regulation 33 of SEBI Regulations.

In terms of Regulations 47 of the SEBI Regulations, the Company will publish Audited Consolidated Financial Results for the quarter and year ended on 31st March, 2016. Both Audited Standalone and Consolidated Financial Results will be available at Company's website www.torrentpharma.com.

2. Press Release on Financial Results including performance highlights as being submitted to the press media.

Considering the distribution of interim dividend & special interim dividend of Rs. 20.00 and Rs. 15.00 (Total Rs. 35 per share) respectively per equity share of Rs 5.00 each for the FY 2015-16, the Board did not recommend distribution of any further dividend.

The above is for your information and record.

Thanking you,

Yours Sincerely,

For TORRENT PHARMACEUTICALS LIMITED

MAHESH AGRAWAL

VP (LEGAL) & COMPANY SECRETARY

Encl.: A/a

CIN: L24230GJ1972PLC002126